Simon, Barry J. sells ImmunityBio (IBRX) shares worth $1.78 million
#ImmunityBio #Barry Simon #IBRX #ANKTIVA #insider trading #biotech stocks #cancer treatment #pharmaceutical partnerships
📌 Key Takeaways
- Barry J. Simon sold 175,000 ImmunityBio shares worth $1.78 million under a pre-arranged trading plan
- ImmunityBio stock has surged 396% year-to-date and 337% over the past six months
- ImmunityBio reported $113 million in revenue for ANKTIVA in 2025, a 700% increase from the previous year
- The company has expanded through partnerships in Europe and the Middle East for its cancer treatment ANKTIVA
📖 Full Retelling
Barry J. Simon, a director of ImmunityBio, Inc. (NASDAQ:IBRX), sold 175,000 shares of common stock on February 20 and 23, 2026, for approximately $1.78 million under a pre-arranged Rule 10b5-1 trading plan. The transactions were executed at prices ranging from $9.25 to $10.2491 per share, occurring as the company's stock trades near its 52-week high of $11, with shares currently valued at $11.54—a remarkable surge that has delivered a 396% return year-to-date and 337% over the past six months. In addition to the share sales, Simon exercised 15,243 Restricted Stock Units on February 22 at no cost and disposed of 6,026 shares to cover tax obligations valued at $52,426, leaving him with a direct ownership of 2,925,821 shares of ImmunityBio following these transactions. The insider trading activity comes amid strong financial performance for ImmunityBio, which reported a significant increase in revenue for its cancer treatment ANKTIVA, reaching $113 million in 2025—a 700% rise compared to the previous year—with fourth-quarter net product revenue climbing to $38.3 million, representing a 20% increase from the third quarter and a 431% rise year-over-year. The company has also expanded its market presence through strategic partnerships, including a collaboration with Accord Healthcare to commercialize ANKTIVA across 30 European countries, following the European Commission's conditional marketing authorization for the treatment in 33 countries, and partnerships with Biopharma and Cigalah Healthcare for distribution in Saudi Arabia and the broader Middle East and North Africa region, with plans to make the treatment available within 60 days after receiving necessary regulatory approvals.
🏷️ Themes
Insider Trading, Biotechnology, Stock Performance, Partnerships
📚 Related People & Topics
Barry Simon
American mathematician
Barry Martin Simon (born 16 April 1946) is an American mathematical physicist and was the IBM professor of Mathematics and Theoretical Physics at Caltech, known for his prolific contributions in spectral theory, functional analysis, and nonrelativistic quantum mechanics (particularly Schrödinger o...
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry AMD stock surges 14% on Meta AI partnership deal Bitcoin slips, wipes out 50% from October record high at session low Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Simon, Barry J. sells ImmunityBio shares worth $1.78 million By Investing.com Insider Trading Published 02/24/2026, 08:10 PM Simon, Barry J. sells ImmunityBio shares worth $1.78 million 0 IBRX 17.40% Director Barry J. Simon of ImmunityBio, Inc. (NASDAQ:IBRX) sold 175,000 shares of common stock on February 20 and 23, 2026, for approximately $1.78 million. The sales were executed at prices ranging from $9.25 to $10.2491. The insider sale comes as the stock trades near its 52-week high of $11, with shares currently at $11.54—a remarkable surge that has delivered a 396% return year-to-date and 337% over the past six months. According to a Form 4 filing with the Securities and Exchange Commission, the sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2024. On February 22, Simon also exercised 15,243 Restricted Stock Units , converting them into common stock. The exercise price for these RSUs was $0. On the same day, 6,026 shares were disposed of to cover tax obligations, with the shares valued at $8.70, totaling $52,426. Following these transactions, Simon directly owns 2,925,821 shares of ImmunityBio. According to InvestingPro analysis, the stock appears overvalued at current levels. Investors can access 12 additional ProTips and comprehensive financial metrics to better evaluate IBRX’s investment potential. In other recent news, ImmunityBio Inc. reported a significant increase in revenue for its cancer treatment ANKTIVA, reaching $113 million in 2025, which marks a 700% rise compared to the previous year. The company’s fourth-quarter net product revenue also showed strong g...
Read full article at source